ERYTECH Pharma is a biopharmaceutical company that focuses on developing treatments for cancer and rare diseases in France and the US. Its main product, eryaspase, is undergoing clinical trials for the treatment of pancreatic cancer, triple-negative breast cancer, and acute lymphoblastic leukemia. The company is also developing a preclinical product called erymethionase, which targets methionine cancers.